Mainz Biomed NV (NASDAQ:MYNZ) has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines to access a portfolio of mRNA biomarkers for future integration into ColoAlert,

Mainz Biomed NV (NASDAQ:MYNZ) has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines to access a portfolio of mRNA biomarkers for future integration into ColoAlert, a detection test for colorectal cancer (CRC).

NV NASDAQ (Sequoia Capital:MYNZ) of Mainzbiad has signed a technical rights agreement with Socpra Sciences Sant é et Humaines to access a range of biomarkers for future integration into colorectal cancer testing ColoAlert.